KLSE:IHH

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

IHH Healthcare Berhad

Executive Summary

IHH Healthcare Berhad, an investment holding company, provides healthcare services. More Details

Rewards

Earnings are forecast to grow 46.33% per year

Risk Analysis

No risks detected for IHH from our risk checks.


Snowflake Analysis

Reasonable growth potential with mediocre balance sheet.


Similar Companies

Share Price & News

How has IHH Healthcare Berhad's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: IHH has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-1.9%

IHH

-1.9%

MY Healthcare

-0.5%

MY Market


1 Year Return

-8.2%

IHH

-7.1%

MY Healthcare

-3.3%

MY Market

Return vs Industry: IHH underperformed the MY Healthcare industry which returned -7.1% over the past year.

Return vs Market: IHH underperformed the MY Market which returned -3.4% over the past year.


Shareholder returns

IHHIndustryMarket
7 Day-1.9%-1.9%-0.5%
30 Day-3.3%-3.5%-3.2%
90 Day-2.4%-1.2%3.9%
1 Year-7.5%-8.2%-6.4%-7.1%-0.3%-3.3%
3 Year-7.4%-9.0%-8.1%-10.2%-6.5%-17.3%
5 Year-10.6%-13.0%-10.7%-13.9%8.5%-10.1%

Price Volatility Vs. Market

How volatile is IHH Healthcare Berhad's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is IHH Healthcare Berhad undervalued compared to its fair value and its price relative to the market?

1.94x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: IHH (MYR5.23) is trading above our estimate of fair value (MYR4.97)

Significantly Below Fair Value: IHH is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: IHH is unprofitable, so we can't compare its PE Ratio to the MY Healthcare industry average.

PE vs Market: IHH is unprofitable, so we can't compare its PE Ratio to the MY market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate IHH's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: IHH's PB Ratio (1.9x) is in line with the MY Healthcare industry average.


Next Steps

Future Growth

How is IHH Healthcare Berhad forecast to perform in the next 1 to 3 years based on estimates from 20 analysts?

46.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: IHH is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.9%).

Earnings vs Market: IHH is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: IHH's is expected to become profitable in the next 3 years.

Revenue vs Market: IHH's revenue (12.3% per year) is forecast to grow faster than the MY market (7.3% per year).

High Growth Revenue: IHH's revenue (12.3% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: IHH's Return on Equity is forecast to be low in 3 years time (4.8%).


Next Steps

  • Explore growth companies in the Healthcare industry.

Past Performance

How has IHH Healthcare Berhad performed over the past 5 years?

-23.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: IHH is currently unprofitable.

Growing Profit Margin: IHH is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: IHH is unprofitable, and losses have increased over the past 5 years at a rate of 23.2% per year.

Accelerating Growth: Unable to compare IHH's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IHH is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (-21.8%).


Return on Equity

High ROE: IHH has a negative Return on Equity (-1.03%), as it is currently unprofitable.


Next Steps

Financial Health

How is IHH Healthcare Berhad's financial position?


Financial Position Analysis

Short Term Liabilities: IHH's short term assets (MYR7.1B) exceed its short term liabilities (MYR6.0B).

Long Term Liabilities: IHH's short term assets (MYR7.1B) do not cover its long term liabilities (MYR11.1B).


Debt to Equity History and Analysis

Debt Level: IHH's debt to equity ratio (34.9%) is considered satisfactory.

Reducing Debt: IHH's debt to equity ratio has increased from 24.3% to 34.9% over the past 5 years.

Debt Coverage: IHH's debt is well covered by operating cash flow (22.3%).

Interest Coverage: IHH is unprofitable, therefore interest payments are not well covered by earnings.


Balance Sheet


Next Steps

Dividend

What is IHH Healthcare Berhad current dividend yield, its reliability and sustainability?

0.76%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: IHH's dividend (0.76%) isn’t notable compared to the bottom 25% of dividend payers in the MY market (1.67%).

High Dividend: IHH's dividend (0.76%) is low compared to the top 25% of dividend payers in the MY market (5%).


Stability and Growth of Payments

Stable Dividend: IHH is not paying a notable dividend for the MY market, therefore no need to check if payments are stable.

Growing Dividend: IHH is not paying a notable dividend for the MY market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: IHH is not paying a notable dividend for the MY market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IHH's dividend in 3 years as they are not forecast to pay a notable one for the MY market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.5yrs

Average management tenure


CEO

Kelvin Loh (46 yo)

0.67

Tenure

RM9,936,000

Compensation

Dr. Chi-Keon Loh, also known as Kelvin, serves as Managing Director and Chief Executive Officer of IHH Healthcare Berhad since January 1, 2020 and serves as its Executive Director since July 01, 2019. He h ...


CEO Compensation Analysis

Compensation vs Market: Kelvin's total compensation ($USD2.38M) is above average for companies of similar size in the MY market ($USD1.17M).

Compensation vs Earnings: Insufficient data to compare Kelvin's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
Chi-Keon Loh
MD, CEO & Executive Director0.67yrRM9.94mno data
Heng Joo Sim
Group Chief Operating Officer0.67yrno datano data
Penelope Koh
Vice President of Investor Relationsno datano datano data
Ida Binti Ab Rahim
Group General Counsel & Company Secretaryno datano datano data
Angela Ryan
Group Chief Human Resources Officer1yrno datano data
Lok Sen Huang
Group Head of Internal Audit7.5yrsno datano data
Nili Shayrina Saat
Group Head of Risk Management1.83yrsno datano data
Boon Kheng Chan
Group Head of Strategic Planning & Business Development (M&A) and CEO of South East Asia Ops. Div.2.67yrsno datano data
Dilip Kadambi
Group Head of Business Transformation0.33yrno datano data
Ching Seow
Company Secretaryno datano datano data
Abdul Baba
President of IMU Health Sdn Bhd and C.E.O. & Vice-Chancellor of IMU Education Sdn Bhd2.67yrsno datano data
Tahsin Guney
Chief Executive Officer of Acibadem Saglik Yatirimlari Holding A.S031.5yrsno datano data

1.5yrs

Average Tenure

48yo

Average Age

Experienced Management: IHH's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Chi-Keon Loh
MD, CEO & Executive Director0.67yrRM9.94mno data
Shirish Apte
Independent Non-Executive Director6yrsRM975.00kno data
Mohammed Bin Hashim
Independent Non Executive Chairman2.67yrsRM978.00kno data
Mehmet Aydinlar
Non-Independent & Non-Executive Director8.67yrsRM9.29m5.92%
MYR 2.7b
Farid Bin Mohamed Sani
Non-Independent & Non-Executive Director0.83yrRM51.00kno data
Jill Watts
Independent Non Executive Director2.42yrsRM485.00kno data
Rossana Binti Ahmad Rashid
Independent Non-Executive Director8.42yrsRM1.14mno data
Takeshi Saito
Non-Independent & Non-Executive Director1.5yrsRM414.00kno data
Masato Sugahara
Non Independent Non Executive Director0.42yrno datano data
Tomo Nagahiro
Non Independent Non Executive Alternate Director0.42yrno datano data
Eugene Wong
Non Independent Non Executive Alternate Director1.17yrsno datano data
Shilin Ong
Non Independent Non Executive Alternate Director1.08yrsno datano data

1.3yrs

Average Tenure

51yo

Average Age

Experienced Board: IHH's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

IHH Healthcare Berhad's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: IHH Healthcare Berhad
  • Ticker: IHH
  • Exchange: KLSE
  • Founded: 2010
  • Industry: Health Care Facilities
  • Sector: Healthcare
  • Market Cap: RM45.905b
  • Shares outstanding: 8.78b
  • Website: https://www.ihhhealthcare.com

Number of Employees


Location

  • IHH Healthcare Berhad
  • Pantai Hospital Kuala Lumpur
  • Level 11, Block A
  • Kuala Lumpur
  • Wilayah Persekutuan
  • 59100
  • Malaysia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IHHKLSE (Bursa Malaysia)YesOrdinary SharesMYMYRJul 2012
Q0FSGX (Singapore Exchange)YesOrdinary SharesSGSGDJul 2012
IHHH.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDJul 2012

Biography

IHH Healthcare Berhad, an investment holding company, provides healthcare services. It provides primary care services, such as treatment of basic illnesses, routine check-ups, and vaccinations. The company ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/26 20:03
End of Day Share Price2020/09/25 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.